Greenberg Richard S 4
4 · NEXIEN BIOPHARMA, INC. · Filed Apr 5, 2021
Insider Transaction Report
Form 4
Greenberg Richard S
DirectorEVP and Chairman10% Owner
Transactions
- Award
Common Stock
2021-04-01+1,000,000→ 3,685,192 total
Holdings
Convertible note
Exercise: $0.04From: 2020-11-24Exp: 2023-11-24→ common stock (1,062,953 underlying)- 2,500,000
Options to purchase common stock (right to buy)
Exercise: $0.08From: 2020-08-19Exp: 2027-08-19→ Common Stock (250,000 underlying) - 1,062,953
Class B Warrant
Exercise: $0.04From: 2020-11-24Exp: 2025-11-24→ common stock (1,062,953 underlying) - 150,000
Options to purchase common stock (right to buy)
Exercise: $0.54From: 2018-07-25Exp: 2025-07-25→ Common Stock (150,000 underlying) - 100,000
Options to purchase common stock (right to buy)
Exercise: $0.66From: 2018-10-26Exp: 2025-10-26→ Common Stock (100,000 underlying) - 1,062,953
Class A Warrant
Exercise: $0.04From: 2020-11-24Exp: 2025-11-24→ common stock (1,062,953 underlying) - 1,062,953
Class C Warrant
Exercise: $0.05From: 2020-11-24Exp: 2025-11-24→ common stock (1,062,953 underlying)
Footnotes (1)
- [F1]1. Issued in lieu of compensation for services.